A Cost-Benefit Analysis of Bivalent Covid-19 Vaccines

Author(s): Dan-Yu Lin, Yangjianchen Xu, Donglin Zeng, Shadia Khan Sunny

The cost-benefit ratios of the bivalent vaccines were unknown. To address this issue, we considered surveillance data on the administration of the Moderna and Pfizer-BioNTech bivalent vaccines and clinical outcomes from September 1, 2022 to February 10, 2023 for North Carolina residents 12 years of age or older. We found that booster vaccination was much more beneficial for people 65 years of age or older than for people 12–64 years of age, mainly because the risks of hospitalization and death were much higher in the older age group.